Compare MFG & ABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFG | ABT |
|---|---|---|
| Founded | 2003 | 1888 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0B | 152.9B |
| IPO Year | 2005 | 2007 |
| Metric | MFG | ABT |
|---|---|---|
| Price | $10.90 | $102.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $130.90 |
| AVG Volume (30 Days) | 3.0M | ★ 5.6M |
| Earning Date | 05-19-2026 | 04-16-2026 |
| Dividend Yield | 1.77% | ★ 2.76% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $44,328,000,000.00 |
| Revenue This Year | N/A | $10.75 |
| Revenue Next Year | $13.54 | $8.10 |
| P/E Ratio | ★ $16.74 | $167.59 |
| Revenue Growth | N/A | ★ 5.67 |
| 52 Week Low | $6.11 | $81.97 |
| 52 Week High | $11.49 | $137.49 |
| Indicator | MFG | ABT |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 37.22 |
| Support Level | $9.72 | $100.88 |
| Resistance Level | $11.06 | $103.84 |
| Average True Range (ATR) | 0.16 | 2.61 |
| MACD | -0.02 | -1.02 |
| Stochastic Oscillator | 29.65 | 15.76 |
Mizuho Financial Group is roughly tied with megabank peer Sumitomo Mitsui Financial Group for the status as Japan's second-largest bank after Mitsubishi UFJ Financial Group. In Japan, Mizuho has more of a corporate focus than SMFG, which has a larger retail business. Its overseas weighting is slightly smaller than that of MUFG. Unlike its two Japanese megabank peers, which own foreign banks outright or hold noncontrolling stakes in local banks overseas, Mizuho expanded in recent years beyond its traditional Japanese borrowers, mainly through its core banking and securities units, focusing on the financing needs of global multinational corporations.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.